- Evolution, Molecular
- Genetic Variation
- Host-Parasite Interactions
- Immunity, Innate
- Insect Vectors
- Malaria, Falciparum
- Evolution, Molecular
Malaria remains a major global health problem leading to significant morbidity and mortality. The World Health Organization reports that about half a million people die of malaria each year with most of these deaths occurring in children in Sub-Saharan Africa. Significant gains in malaria control have been made in recent years largely on the backs of concerted vector control efforts including the use of bed nets and insecticide. Our area of research focuses on understanding the dynamics of the relationship between the mosquito vector and the malaria parasite, Plasmodium falciparum.
Genetics of malaria susceptibility
Genetic variation is the currency of evolutionary adaptation and is a potentially powerful future avenue in the pursuit of new malaria control tools. This is particularly true at the current moment, when existing simple malaria control tools (e.g., insecticides, drugs, and bednets) are failing due to rapid evolutionary responses of the vector and parasite. Thus, understanding the strong natural genetic mechanisms that underlie mosquito infection with Plasmodium could lead to new malaria control tools that are naturally rooted in the genome and ecology of the vector.
Using mosquito families initiated in nature in West Africa, we have used genetic mapping techniques to identify a major genetic locus with strong control over malaria infection in nature (Riehle et al. Science 2006, Riehle et al., Malaria Journal 2007). Now, with improved sequencing technologies we are employing individual genome sequencing to identify the causative variants underlying malaria susceptibility and resistance segregating in nature. Once in hand, we will functionally characterize the mechanism by which genetic variation impacts malaria infection.
The mosquito microbiome and mosquito immunity
Studies of the microbiome have risen exponentially in recent years as components of the gut ecosystem are linked to numerous important health problems. We are interested in characterizing both the prokaryotic and eukaryotic microbiome of mosquito vectors and tying this to mosquito immune function. Mosquito larvae have an aquatic lifestyle and are continually exposed to environmental microbes throughout their larval development. Some of these environmental microbes are closely related to the same parasites that cause malaria. We hypothesize that repeated exposure to prokaryotic and eukaryotic microbes during their development has an impact on mosquito immunity and has shaped the mosquito response to malaria infection. Compared to the prokaryotic microbiome, relatively little is known about the eukaryotic microbiome as it is technically more challenging to profile. To this end we worked out a peptide nucleic acid blocker (PNA Blocker) technique which selectively represses amplification of 18S target from mosquito template enriching for amplification from mosquito associated eukaryotic microbes. (Belda et al., Scientific Reports, 2017)
Understanding the role of noncoding variants in important disease phenotypes
It is well known from model systems like humans and mice that the vast majority (>90%) of SNPs associated with genome wide association studies (GWAS) lie in the non-coding portion of the genome. However, as there is no amino acid by which to interpret functional consequences within the non-coding region we have no way to identify nor interpret function for non-coding elements. One important class of non-coding elements is enhancers which are short DNA sequences that modulate expression for suites of genes and act independent of position or orientation in the genome. Despite their known role in gene expression regulation, until recently there has not been a method for high-throughput, direct and quantitative screening of DNA sequences for enhancer activity. Indirect screening methods like ChIP-seq and DNase-seq can infer the presence of enhancers active in a particular cell type and developmental stage, by detecting the open chromatin state correlated with binding of trans-acting factors and histone modification. However, inactive enhancers are hidden by histone assembly into closed chromatin, and thus indirect chromatin-based assays like ChIP-seq and DNase-seq only detect the subset of enhancers active in the cell type, and at the time they were tested. Further, chromatin-based assays indirectly infer the positions of enhancers, but they do not directly assay enhancer activity. In contrast, the STARR-seq assay (Self-Transcribing Active Regulatory Region sequencing) is a massively parallel reporter assay that detects enhancers directly by their functional properties, querying millions of DNA fragments simultaneously. STARR-seq is in essence a simultaneous genome wide luciferase assay, with the notable exception that it measures enhancer-dependent transcript levels, rather than light output due to translated protein.
Using this STARR-seq technique we have generated genome wide maps of transcriptional enhancers for two sister taxa of malaria vectors, Anopheles coluzzii and Anopheles gambiae and with this map in hand we are now able to better identify functional noncoding variants with roles in malaria susceptibility. Additionally, we are able to query non-coding variants that may underlie the differences between these two malaria vector species that differ mostly in their ecology and behavior and not in their susceptibility to malaria. However, the fact that A. coluzzii occupies urban niches which A. gambiae tends to avoid potentially increases malaria transmission due to an expansion of transmission range.
The STARR-seq assay, right
1) Genomic DNA is randomly sheared. 2) Resulting ~1 kb fragments are adapter-ligated and cloned into expression vector. 3) 4a3a hemocyte-like Anopheles cell line is transfected with cloned library of genomic fragments. 4) After 24h, mRNA is isolated from cell line (plasmid DNA also isolated as input control). 5) Insert specific cDNA is synthesized. 6) Paired end Illumina sequencing. 7) Align sequence reads to the genome. 8) Normalized read depth (y-axis) indicates relative enhancer activity across the genome (x-axis).
(Nardini L, Holm I, Pain A, Bischoff E, Gohl DM, Zongo S, Guelbeogo WM, Sagnon N, Vernick KD, Riehle MM.) Sci Rep. 2019 Oct 24;9(1):15275 PMID: 31649293 PMCID: PMC6813320 SCOPUS ID: 2-s2.0-85074074218 10/28/2019
(Anopheles gambiae 1000 Genomes Consortium, Data analysis group, Partner working group, Sample collections—Angola:, Burkina Faso:, Cameroon:, Gabon:, Guinea:, Guinea-Bissau:, Kenya:, Uganda:, Crosses:, Sequencing and data production, Web application development, Project coordination.) Nature. 2017 12 07;552(7683):96-100 PMID: 29186111 PMCID: PMC6026373 SCOPUS ID: 2-s2.0-85038811995 12/01/2017
(Riehle MM, Bukhari T, Gneme A, Guelbeogo WM, Coulibaly B, Fofana A, Pain A, Bischoff E, Renaud F, Beavogui AH, Traore SF, Sagnon N, Vernick KD.) Elife. 2017 06 23;6 PMID: 28643631 PMCID: PMC5482571 SCOPUS ID: 2-s2.0-85021397890 06/24/2017
(Belda E, Coulibaly B, Fofana A, Beavogui AH, Traore SF, Gohl DM, Vernick KD, Riehle MM.) Sci Rep. 2017 06 12;7(1):3241 PMID: 28607435 PMCID: PMC5468309 SCOPUS ID: 2-s2.0-85020718351 06/14/2017
(Mitri C, Bischoff E, Takashima E, Williams M, Eiglmeier K, Pain A, Guelbeogo WM, Gneme A, Brito-Fravallo E, Holm I, Lavazec C, Sagnon N, Baxter RH, Riehle MM, Vernick KD.) PLoS Pathog. 2016 Aug;12(8):e1005836 PMID: 27518517 PMCID: PMC4982601 08/16/2016
(Coulibaly B, Kone R, Barry MS, Emerson B, Coulibaly MB, Niare O, Beavogui AH, Traore SF, Vernick KD, Riehle MM.) Malar J. 2016 Apr 08;15:191 PMID: 27059057 PMCID: PMC4826509 SCOPUS ID: 2-s2.0-84966415575 04/10/2016
(Crawford JE, Riehle MM, Markianos K, Bischoff E, Guelbeogo WM, Gneme A, Sagnon N, Vernick KD, Nielsen R, Lazzaro BP.) Mol Ecol. 2016 Apr;25(7):1494-510 PMID: 26846876 SCOPUS ID: 2-s2.0-84960921872 02/06/2016
(Markianos K, Bischoff E, Mitri C, Guelbeogo WM, Gneme A, Eiglmeier K, Holm I, Sagnon N, Vernick KD, Riehle MM.) PLoS One. 2016;11(1):e0145308 PMID: 26731649 PMCID: PMC4701492 SCOPUS ID: 2-s2.0-84953889084 01/06/2016
(Mitri C, Bischoff E, Takashima E, Williams M, Eiglmeier K, Pain A, Guelbeogo WM, Gneme A, Brito-Fravallo E, Holm I, Lavazec C, Sagnon N, Baxter RH, Riehle MM, Vernick KD.) PLoS Pathog. 2015 Dec;11(12):e1005306 PMID: 26633695 PMCID: PMC4669117 SCOPUS ID: 2-s2.0-84953266859 12/04/2015
(Crawford JE, Riehle MM, Guelbeogo WM, Gneme A, Sagnon N, Vernick KD, Nielsen R, Lazzaro BP.) Genome Biol Evol. 2015 Nov 28;7(11):3116-31 PMID: 26615027 PMCID: PMC4994751 SCOPUS ID: 2-s2.0-84957077006 11/29/2015
(Redmond SN, Eiglmeier K, Mitri C, Markianos K, Guelbeogo WM, Gneme A, Isaacs AT, Coulibaly B, Brito-Fravallo E, Maslen G, Mead D, Niare O, Traore SF, Sagnon N, Kwiatkowski D, Riehle MM, Vernick KD.) BMC Genomics. 2015 Oct 13;16:779 PMID: 26462916 PMCID: PMC4603968 SCOPUS ID: 2-s2.0-84945219062 10/16/2015
(Mitri C, Markianos K, Guelbeogo WM, Bischoff E, Gneme A, Eiglmeier K, Holm I, Sagnon N, Vernick KD, Riehle MM.) Malar J. 2015 Oct 06;14:391 PMID: 26445487 PMCID: PMC4596459 SCOPUS ID: 2-s2.0-84943228821 10/09/2015